Houlihan Lokey Advises Falfurrias Management Partners
Houlihan Lokey is pleased to announce that Falfurrias Management Partners (Falfurrias), a Charlotte-based private equity firm focused on growth-oriented, middle-market businesses, has invested in Jumo Health, an innovative and award-winning clinical trial solutions company. The terms of the transaction were not disclosed.
While clinical trials suffer from low enrollment, high dropout rates, and a startling lack of diverse representation, Jumo Health’s solutions aim to remedy these critical industry problems. Jumo Health’s curriculum-based educational solutions ensure prospective clinical trial participants have information relevant to their age, gender, race, language, and socioeconomic status at every stage of their journey, from preconsent trial awareness to ongoing trial engagement. The results are faster recruitment, longer retention, increased patient compliance, and greater overall trial success for sponsors.
The Falfurrias investment will bring new resources and expertise to the Jumo Health team, aimed at expanding the organization’s core capabilities, enabling data-driven solutions, and widening patient engagement. Specifically, Falfurrias is energized by Jumo Health’s commitment to improving access to clinical trials among traditionally underrepresented communities, many of whom have a deep-seated mistrust of the healthcare system due to historical inequities. Jumo Health has taken tangible steps to rebuild this trust by creating culturally sensitive materials and establishing a robust network of patient advocacy groups and more than 2,000 religious, social, government, and community-based organizations.
Equity for this investment comes from Falfurrias Capital Partners V, an operationally focused, lower-middle-market private equity fund focused on investing in high-growth companies in the food manufacturing, industrial technology, and business services sectors, and builds on the firm’s experience in marketing and communications. The team comprises investors and proven operators as well as in-house resources across strategy and market insights, finance and integration, human capital, and technology. Adam Cossman, an executive advisor on the Falfurrias team with 25 years of pharmaceutical commercialization experience, will join Jumo Health’s board of directors as Chairman. Alexander Jutkowitz, an executive in residence at Falfurrias and global content marketing and communications expert, and Jackie Kent, a pharmaceutical executive with nearly 30 years of clinical trial innovation experience, will also join the board of directors.
Houlihan Lokey served as the exclusive financial advisor to Falfurrias.